The latest price target for Bolt Biotherapeutics (NASDAQ:BOLT) was reported by HC Wainwright & Co. on March 13, 2026. The analyst firm set a price target for $7.00 expecting BOLT to rise to within 12 months (a possible 41.13% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Bolt Biotherapeutics (NASDAQ:BOLT) was provided by HC Wainwright & Co., and Bolt Biotherapeutics reiterated their buy rating.

The last upgrade for Bolt Biotherapeutics Inc happened on May 12, 2023 when SVB Leerink raised their price target to $4. SVB Leerink previously had a market perform for Bolt Biotherapeutics Inc.

The last downgrade for Bolt Biotherapeutics Inc happened on May 15, 2024 when Leerink Partners changed their price target from $3 to $1 for Bolt Biotherapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bolt Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bolt Biotherapeutics was filed on March 13, 2026 so you should expect the next rating to be made available sometime around March 13, 2027.

While ratings are subjective and will change, the latest Bolt Biotherapeutics (BOLT) rating was a reiterated with a price target of $7.00 to $7.00. The current price Bolt Biotherapeutics (BOLT) is trading at is $4.96, which is out of the analyst’s predicted range.